Horizon Therapeutics [HZNP] vs Pfizer [PFE] Detailed Stock Comparison
Horizon Therapeutics
NASDAQ
Loading...
Pfizer
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Horizon Therapeutics wins in 8 metrics, Pfizer wins in 9 metrics, with 0 ties. Pfizer appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Horizon Therapeutics | Pfizer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 61.86 | 13.62 | Pfizer |
| Price-to-Book Ratio | 5.01 | 1.65 | Pfizer |
| Debt-to-Equity Ratio | 0.48 | 69.70 | Horizon Therapeutics |
| PEG Ratio | -16.29 | 0.00 | Horizon Therapeutics |
| EV/EBITDA | 24.08 | 7.98 | Pfizer |
| Profit Margin (TTM) | 74.64% | 16.84% | Horizon Therapeutics |
| Operating Margin (TTM) | 16.83% | 28.68% | Pfizer |
| EBITDA Margin (TTM) | 16.83% | 28.68% | Pfizer |
| Return on Equity | 10.28% | 12.17% | Pfizer |
| Return on Assets (TTM) | 5.72% | 5.25% | Horizon Therapeutics |
| Free Cash Flow (TTM) | N/A | $9.84B | N/A |
| Dividend Yield | N/A | 5.32% | N/A |
| 1-Year Return | -6.82% | -10.45% | Horizon Therapeutics |
| Price-to-Sales Ratio (TTM) | 7.34 | 2.29 | Pfizer |
| Enterprise Value | $26.84B | $195.46B | Pfizer |
| EV/Revenue Ratio | 7.40 | 3.06 | Pfizer |
| Gross Profit Margin (TTM) | 76.72% | 74.22% | Horizon Therapeutics |
| Revenue per Share (TTM) | $16 | $11 | Horizon Therapeutics |
| Earnings per Share (Diluted) | $2.22 | $1.89 | Horizon Therapeutics |
| Beta (Stock Volatility) | N/A | 0.44 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Horizon Therapeutics vs Pfizer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pfizer | 0.54% | 2.94% | 2.94% | 12.33% | -2.89% | -2.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | -6.82% | 74.04% | 9.84% | 176.66% | 176.66% | 176.66% |
| Pfizer | -10.45% | -44.72% | -28.05% | -16.49% | 69.48% | 9.61% |
Performance & Financial Health Analysis: Horizon Therapeutics vs Pfizer
| Metric | HZNP | PFE |
|---|---|---|
| Market Information | ||
| Market Cap | $26.63B | $146.35B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 19,134,206 | 35,339,010 |
| 90 Day Avg. Volume | 8,460,695 | 42,773,080 |
| Last Close | $116.30 | $25.88 |
| 52 Week Range | $116.30 - $116.34 | $20.92 - $30.43 |
| % from 52W High | -0.03% | -14.95% |
| All-Time High | $39.49 (Jul 20, 2015) | $61.71 (Dec 20, 2021) |
| % from All-Time High | 194.50% | -58.06% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.10% |
| Quarterly Earnings Growth | N/A | 69.98% |
| Financial Health | ||
| Profit Margin (TTM) | 0.75% | 0.17% |
| Operating Margin (TTM) | 0.17% | 0.29% |
| Return on Equity (TTM) | 0.10% | 0.12% |
| Debt to Equity (MRQ) | 0.48 | 69.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $23.22 | $15.60 |
| Cash per Share (MRQ) | N/A | $2.33 |
| Operating Cash Flow (TTM) | $1.33B | $15.19B |
| Levered Free Cash Flow (TTM) | $1.81B | $16.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 5.32% |
| Last 12-Month Dividend | N/A | $1.27 |
Valuation & Enterprise Metrics Analysis: Horizon Therapeutics vs Pfizer
| Metric | HZNP | PFE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 61.86 | 13.62 |
| Forward P/E | 20.55 | 8.78 |
| PEG Ratio | -16.29 | 0.00 |
| Price to Sales (TTM) | 7.34 | 2.29 |
| Price to Book (MRQ) | 5.01 | 1.65 |
| Market Capitalization | ||
| Market Capitalization | $26.63B | $146.35B |
| Enterprise Value | $26.84B | $195.46B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.40 | 3.06 |
| Enterprise to EBITDA | 24.08 | 7.98 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.44 |
| Book Value per Share (MRQ) | $23.22 | $15.60 |
Financial Statements Comparison: Horizon Therapeutics vs Pfizer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HZNP | PFE |
|---|---|---|
| Revenue/Sales | N/A | $13.72B |
| Cost of Goods Sold | N/A | $2.85B |
| Gross Profit | N/A | $10.87B |
| Research & Development | N/A | $2.20B |
| Operating Income (EBIT) | N/A | $4.43B |
| EBITDA | N/A | $6.48B |
| Pre-Tax Income | N/A | $2.79B |
| Income Tax | N/A | $-189.00M |
| Net Income (Profit) | N/A | $2.97B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HZNP | PFE |
|---|---|---|
| Cash & Equivalents | N/A | $1.43B |
| Total Current Assets | N/A | $45.86B |
| Total Current Liabilities | N/A | $36.45B |
| Long-Term Debt | N/A | $56.82B |
| Total Shareholders Equity | N/A | $90.64B |
| Retained Earnings | N/A | $119.59B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HZNP | PFE |
|---|---|---|
| Operating Cash Flow | N/A | $3.91B |
| Capital Expenditures | N/A | $-564.00M |
| Free Cash Flow | N/A | $1.77B |
| Debt Repayment | N/A | $-2.43B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HZNP | PFE |
|---|---|---|
| Shares Short | N/A | 107.78M |
| Short Ratio | N/A | 2.67 |
| Short % of Float | N/A | 0.02% |
| Average Daily Volume (10 Day) | 19,134,206 | 35,339,010 |
| Average Daily Volume (90 Day) | 8,460,695 | 42,773,080 |
| Shares Outstanding | 229.00M | 5.67B |
| Float Shares | N/A | 5.68B |
| % Held by Insiders | N/A | 0.00% |
| % Held by Institutions | N/A | 0.67% |
Dividend Analysis & Yield Comparison: Horizon Therapeutics vs Pfizer
| Metric | HZNP | PFE |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.27 |
| Last 12-Month Dividend Yield | N/A | 5.32% |
| 3-Year Avg Annual Dividend | N/A | $1.52 |
| 3-Year Avg Dividend Yield | N/A | 1.27% |
| 3-Year Total Dividends | N/A | $4.55 |
| Ex-Dividend Date | N/A | Jan 24, 2025 |